Robotic-assisted radical cystectomy with intracorporeal urinary diversion: Initial South Australian experience

IF 0.2 Q4 UROLOGY & NEPHROLOGY
Andrew R H Shepherd, Zachary Bunjo, P. Sutherland, Andrew Fuller
{"title":"Robotic-assisted radical cystectomy with intracorporeal urinary diversion: Initial South Australian experience","authors":"Andrew R H Shepherd, Zachary Bunjo, P. Sutherland, Andrew Fuller","doi":"10.1177/20514158221084828","DOIUrl":null,"url":null,"abstract":"The aim of this study was to describe the initial experience with robotic-assisted radical cystectomy (RARC) with intracorporeal urinary diversion (ICUD) performed by two robotic surgeons at a single, Australian centre. Retrospective analysis was conducted on 30 consecutive patients who underwent RARC with ICUD with curative intent for muscle-invasive and high-risk non-muscle-invasive bladder cancer between 2017 and 2021. Variables analysed included patient baseline characteristics, operative and peri-operative outcomes, as well as short-term pathological outcomes. A total 30 patients were included; 87% were male and the median age was 71 years. Half of patients had muscle-invasive bladder cancer and 93% had ileal conduit formation (with the remaining two patients undergoing neobladder formation). The median operating time was 247 minutes. The median estimated blood loss was 450 mL and 20% of patients received a blood transfusion. A high-grade complication (Clavien III–V) was encountered in 13% of patients post-operatively. At 90 days, 30 overall complications (Clavien I–V) occurred across 67% of the patients. This series provides further support for the safe introduction of RARC with ICUD in Australia. Further studies with extended duration of follow-up, including oncological outcomes, are required to support widespread adoption of RARC. Level 4 (case series)","PeriodicalId":15471,"journal":{"name":"Journal of Clinical Urology","volume":" ","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2022-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20514158221084828","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The aim of this study was to describe the initial experience with robotic-assisted radical cystectomy (RARC) with intracorporeal urinary diversion (ICUD) performed by two robotic surgeons at a single, Australian centre. Retrospective analysis was conducted on 30 consecutive patients who underwent RARC with ICUD with curative intent for muscle-invasive and high-risk non-muscle-invasive bladder cancer between 2017 and 2021. Variables analysed included patient baseline characteristics, operative and peri-operative outcomes, as well as short-term pathological outcomes. A total 30 patients were included; 87% were male and the median age was 71 years. Half of patients had muscle-invasive bladder cancer and 93% had ileal conduit formation (with the remaining two patients undergoing neobladder formation). The median operating time was 247 minutes. The median estimated blood loss was 450 mL and 20% of patients received a blood transfusion. A high-grade complication (Clavien III–V) was encountered in 13% of patients post-operatively. At 90 days, 30 overall complications (Clavien I–V) occurred across 67% of the patients. This series provides further support for the safe introduction of RARC with ICUD in Australia. Further studies with extended duration of follow-up, including oncological outcomes, are required to support widespread adoption of RARC. Level 4 (case series)
机器人辅助根治性膀胱切除术合并体内尿路改道:南澳大利亚的初步经验
本研究的目的是描述由两名机器人外科医生在一个澳大利亚中心进行的机器人辅助根治性膀胱切除术(RARC)和体内尿路改道术(ICUD)的初步经验。对2017年至2021年间连续30例接受RARC和ICUD治疗的癌症患者进行了回顾性分析,这些患者的治疗目的是治疗肌肉浸润性和高危非肌肉浸润性膀胱癌。分析的变量包括患者基线特征、手术和围手术期结果以及短期病理结果。共纳入30名患者;87%为男性,中位年龄71岁。一半的患者患有肌肉浸润性膀胱癌症,93%的患者形成了回肠导管(其余两名患者正在进行新膀胱形成)。中位手术时间为247分钟。估计的中位失血量为450毫升,20%的患者接受了输血。13%的患者在术后出现高级别并发症(Clavien III-V)。在90天时,67%的患者出现了30例总体并发症(Clavien I-V)。本系列为澳大利亚ICUD安全引入RARC提供了进一步的支持。需要进行进一步的研究,延长随访时间,包括肿瘤学结果,以支持广泛采用RARC。第4级(案例系列)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical Urology
Journal of Clinical Urology UROLOGY & NEPHROLOGY-
CiteScore
0.60
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信